{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:40:42Z","timestamp":1753879242718,"version":"3.41.2"},"reference-count":42,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["21153MFDS602"],"award-info":[{"award-number":["21153MFDS602"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Nephrology"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Cyclic corticosteroid\u2010cyclophosphamide or cyclosporine is a well\u2010known membranous nephropathy (MN) treatment but has high risks of adverse drug reactions (ADRs). Rituximab has a non\u2010inferior effect compared to previous treatments, with fewer ADRs. However, the high cost of rituximab is a pharmacoeconomic disincentive.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a cost\u2010minimisation analysis to evaluate the relative and absolute costs of rituximab versus corticosteroid\u2010cyclophosphamide or cyclosporine in patients with MN over 2\u2009years using a decision\u2010tree model based on ADRs from two pivotal trials (RI\u2010CYCLO and MENTOR). We included costs of medication, time, transportation, and ADRs. Deterministic sensitivity analysis and threshold analysis were performed to assess the uncertainty of the model input parameters and estimate the appropriate price of rituximab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The total expected cost for rituximab was $4132, and $2684 for the comparators, with an expected incremental cost of $1448. Despite a 2.8 times higher medication cost, rituximab reduced ADR costs by 96.3% ($223), time costs by 31.1% ($280), and transportation costs by 46.8% ($180). A 46.9% price reduction of rituximab would make it an economically favourable option for treating MN compared to comparators.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>If the price of rituximab is reduced, it can be a good alternative to corticosteroid\u2010cyclophosphamide or cyclosporine for MN in the Republic of Korea.<\/jats:p><\/jats:sec>","DOI":"10.1111\/nep.70063","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T11:14:48Z","timestamp":1749554088000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Economic Evaluation of Rituximab Versus Corticosteroid\u2010Cyclophosphamide or Cyclosporine in Patients With Membranous Nephropathy in Republic of Korea"],"prefix":"10.1111","volume":"30","author":[{"given":"Heejung","family":"Choi","sequence":"first","affiliation":[{"name":"Department of Nephrology Ajou University School of Medicine  Suwon Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Biohealth Regulatory Science Graduate School of Ajou University  Suwon Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2611-7333","authenticated-orcid":false,"given":"Minjeong","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Nephrology Ajou University School of Medicine  Suwon Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji\u2010Woo","family":"Yun","sequence":"additional","affiliation":[{"name":"Department of Biohealth Regulatory Science Graduate School of Ajou University  Suwon Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hankil","family":"Lee","sequence":"additional","affiliation":[{"name":"College of Pharmacy Ewha Womans University  Seoul Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9912-5393","authenticated-orcid":false,"given":"Inwhee","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Nephrology Ajou University School of Medicine  Suwon Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.09.048"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.11761116"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0270\u20109295(03)00049\u20104"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.015"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1681\/asn.V93444"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2007020166"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2020071091"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814427"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2012020181"},{"key":"e_1_2_10_11_1","unstructured":"The Korean Society of Nephrology \u201cA Numerical Breakdown of Glomerular Diseases in South Korea in Factsheet News \u201d2019accessed 6 February 2025 https:\/\/ksn.or.kr\/bbs\/skin\/publication\/download.php?code=Factsheet&number=1573."},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524\u20104733.2009.00625.x"},{"key":"e_1_2_10_13_1","unstructured":"Health Insurance Review & Assessment Service (HIRA) Bigdata Open portal \u201cStatistics on Subclassification of Diseases (4 Level Classification) \u201daccessed 6 February 2025 https:\/\/opendata.hira.or.kr\/op\/opc\/olap4thDsInfoTab1.do#none."},{"key":"e_1_2_10_14_1","unstructured":"Health Insurance Review and Assessment Service \u201cGuidelines for Economics Evaluation of Pharmaceuticals in Korea \u201d2021accessed 6 February 2025 https:\/\/repository.hira.or.kr\/handle\/2019.oak\/2541."},{"key":"e_1_2_10_15_1","unstructured":"National Health Insurance Service \u201cNational Health Screening Statistics: Average Weight Distribution by City\/Age\/Gender \u201d2024accessed 6 February 2025 https:\/\/kosis.kr\/statHtml\/statHtml.do?orgId=350&tblId=DT_35007_N132&conn_path=I2."},{"key":"e_1_2_10_16_1","unstructured":"Health Insurance Review & Assessment Service \u201cPharmaceutical Benefit List (2022.12.01.) \u201d2022accessed 6 February 2025 https:\/\/www.hira.or.kr\/bbsDummy.do?pgmid=HIRAA030014050000&brdScnBltNo=4&brdBltNo=1659&pageIndex=2&pageIndex2=2."},{"key":"e_1_2_10_17_1","unstructured":"Health Insurance Review & Assessment Service \u201cMedical Fee for Service (2022.01.01.) \u201d2021accessed 6 February 2025 https:\/\/www.hira.or.kr\/bbsDummy.do?pgmid=HIRAA020002000100&brdScnBltNo=4&brdBltNo=9354&pageIndex=1."},{"key":"e_1_2_10_18_1","unstructured":"Statistics Korea \u201cSummary of Economically Active Pop. By Gender \u201d2025accessed 6 February 2025 https:\/\/kosis.kr\/statHtml\/statHtml.do?orgId=101&tblId=DT_1DA7001S&conn_path=I2."},{"key":"e_1_2_10_19_1","unstructured":"Ministry of Employment and Labor \u201cLabor Conditions by Employment Type: Average Hourly Wage by Age \u201d2024accessed 6 February 2025 https:\/\/kosis.kr\/statHtml\/statHtml.do?orgId=118&tblId=DT_118N_LCE0004&conn_path=I2."},{"key":"e_1_2_10_20_1","unstructured":"Y.Kim S.Shin J.Park et\u00a0al. \u201cCosting Methods in Healthcare \u201d2013accessed 6 February 2025 https:\/\/www.neca.re.kr\/SKIN_DIR\/doc.html?fn=6838720130417153731.pdf&rs=\/upload\/synap\/202311."},{"key":"e_1_2_10_21_1","unstructured":"Statistics Korea \u201cCPI by Item (Expenditure Category: 2020=100) \u201d2025accessed 6 February 2025 https:\/\/kosis.kr\/statHtml\/statHtml.do?orgId=101&tblId=DT_1J22001&conn_path=I2."},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2017.036"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.07.028"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.4103\/0971\u20104065.53321"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.15171\/jnp.2019.25"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10102154"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021744"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110633"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001470050708"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.5301\/jn.5000174"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102710.2008.01000.x"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfx295"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1002117"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.08880813"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21984"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2016040449"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002628"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00774\u2010017\u20100867\u2010y"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198\u2010013\u20102515\u20102"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy049"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae084"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913\u2010021\u201006919\u2010x"},{"key":"e_1_2_10_43_1","unstructured":"Health Insurance Review & Assessment Service \u201cPharmaceutical Benefit List (2025.05.01.) \u201d2025accessed 15 May 2025 https:\/\/www.hira.or.kr\/bbsDummy.do?pgmid=HIRAA030014050000&brdScnBltNo=4&brdBltNo=1691&pageIndex=1&pageIndex2=1."}],"container-title":["Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nep.70063","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T23:13:50Z","timestamp":1750634030000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/nep.70063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1111\/nep.70063"],"URL":"https:\/\/doi.org\/10.1111\/nep.70063","archive":["Portico"],"relation":{},"ISSN":["1320-5358","1440-1797"],"issn-type":[{"type":"print","value":"1320-5358"},{"type":"electronic","value":"1440-1797"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"2025-02-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70063"}}